on a mobile?
vTap
    Loading...
 
 
Video
Near-term it may not be too negative from a cash and from returns perspective but in the medium-term the strategic view has to be negative, if Taro is indeed going to slip out of Sun’s hand.
6 months ago
moneycontrol.com
Keep this video in the "Saved" list
Go to Feed to see what's new!
share
keep
 
 
6 months ago
NDTV.COM
Keep this video in the "Saved" list
Go to Feed to see what's new!
share
keep
 
 
6 months ago
NDTV.COM
Keep this video in the "Saved" list
Go to Feed to see what's new!
share
keep
 
 
25875
Sun Pharma said Taro is not entitled to terminate the merger, reports CNBC-TV18, quoting sources. According to the Indian pharma major, the merger offer of USD 10.25 per share is in the best interest ...
6 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
CNBC-TV18
CNBC
Go to Feed to see what's new!
share
keep
 
 
6 months ago
NDTV.COM
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
Mark Mobius
Go to Feed to see what's new!
share
keep
 
 
More Videos
 
Keep this video in the "Saved" list
Go to Feed to see what's new!
share
keep
 
 
 
 
1575
Sun Pharma expresses concern over Taro's decision to sell its Irish plant, reports CNBC-TV18. "The Irish plant sell-off is an effort to discourage Sun from acquiring Taro. We are vigorously disputing the termination of merger agreement by Taro."
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
CNBC-TV18
Mergers and acquisitions
CNBC
Go to Feed to see what's new!
share
keep
 
 

Corporate Home Corporate Home News FAQ About Contact Forums Send Feedback
Privacy Policy and Terms of Use